Hematopoiesis News Volume 11.34 | Sep 1 2020

May 12, 2022

HN 11.34 | 1 Sep 2020

Hematopoiesis News by STEMCELL Technologies

Vol. 11.34 – 1 September, 2020

TOP STORY

Covalent Inhibition of NSD1 Histone Methyltransferase

Compound BT5 demonstrated on-target activity in NUP98-nuclear receptor-binding SET domain (NSD)1 leukemia cells, including inhibition of histone H3 lysine 36 dimethylation and downregulation of target genes, and impaired colony formation in an NUP98-NSD1 patient sample.
[Nature Chemical Biology]

Abstract

Learn more about cGMP-manufactured StemSpan™-ACF Without Phenol Red for culturing hematopoietic cell therapy products

PUBLICATIONSRanked by the impact factor of the journal

PRC2
Insufficiency Causes p53-Dependent Dyserythropoiesis in Myelodysplastic Syndrome

Researchers demonstrated that severe polycomb repressive complex 2 (PRC2) insufficiency induced by the deletion of one allele Ezh1 in Ezh2-deficient mice caused advanced dyserythropoiesis accompanied by a differentiation block and enhanced apoptosis in erythroblasts.
[Leukemia]

Abstract

Inducible
Deletion of CDK4 and CDK6 – Deciphering CDK4/6 Inhibitor Effects in the Hematopoietic System

Total CDK6 knockout mice accumulated the most dormant fraction of hematopoietic stem cells due to an impaired exit of the quiescent state. Researchers recapitulated this finding by deleting CDK6 in adult hematopoiesis.
[Haematologica]

Abstract

A
Single Metabolite which Modulates Lipid Metabolism Alters Hematopoietic Stem/Progenitor Cell Behavior and Promotes Lymphoid Reconstitution

Scientists assessed whether malonyl-CoA could be exploited to steer the behavior of hematopoietic stem/progenitor cells, quiescent stem cells of clinical relevance.
[Stem Cell Reports]

Full Article Graphical Abstract

Arterial
Endothelium Creates a Permissive Niche for Expansion of Human Cord Blood Hematopoietic Stem and Progenitor Cells

A novel strategy was developed to support ex vivo expansion of hematopoietic stem and progenitor cells by coculture with engineered human umbilical arterial endothelial cells, which expressed E4ORF1 stably by using a retroviral system.
[Stem Cell Research & Therapy]

Full Article

CLINICAL RESEARCH

Vascular Access for Optimal Hematopoietic Stem Cell Collection

The authors performed a comparative, retrospective, single‐center study of hematopoietic stem cell collection using these two types of vascular access.
[Journal of Clinical Apheresis]

Abstract

Haploidentical
Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Osteopetrosis and other Nonmalignant Diseases

The authors report their experience with nine pediatric patients with nonmalignant diseases who were transplanted from a haploidentical donor with post-transplant cyclophosphamide.
[Bone Marrow Transplantation]

Full Article

Prevalence
and Clinical Implications of Germline Predisposition Gene Mutations in Patients with Acute Myeloid Leukemia

Researchers performed genomic sequencing of Korean patients diagnosed with acute myeloid leukemia to identify the prevalence and characteristics of germline predisposition mutations.
[Scientific Reports]

Abstract

Dr. Jackie Damen discusses why the CFU assay should be a vital part of your cell therapy workflow in this on-demand webinar.

REVIEWS

Hematopoietic Reprogramming Entangles with Hematopoiesis

Scientists focus on both autogenous and artificial hematopoietic reprogramming under physiological and pathological conditions that is mainly directed by the actions of transcription factors, chemical compounds, or extracellular cytokines.
[Trends in Cell Biology]

Abstract

INDUSTRY AND POLICY NEWS

Astex Pharmaceuticals Announces that Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-Cell Lymphomas by the US FDA

Astex Pharmaceuticals, Inc. announced that the FDA has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins, tolinapant, for the treatment of T-cell lymphoma.
[Astex Pharmaceuticals, Inc]

Press Release

FEATURED EVENT

Covalent Inhibition of NSD1 Histone Methyltransferase

PRC2
Insufficiency Causes p53-Dependent Dyserythropoiesis in Myelodysplastic Syndrome

Inducible
Deletion of CDK4 and CDK6 – Deciphering CDK4/6 Inhibitor Effects in the Hematopoietic System

A
Single Metabolite which Modulates Lipid Metabolism Alters Hematopoietic Stem/Progenitor Cell Behavior and Promotes Lymphoid Reconstitution

Arterial
Endothelium Creates a Permissive Niche for Expansion of Human Cord Blood Hematopoietic Stem and Progenitor Cells

Vascular Access for Optimal Hematopoietic Stem Cell Collection

Haploidentical
Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Osteopetrosis and other Nonmalignant Diseases

Prevalence
and Clinical Implications of Germline Predisposition Gene Mutations in Patients with Acute Myeloid Leukemia

Hematopoietic Reprogramming Entangles with Hematopoiesis

Astex Pharmaceuticals Announces that Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-Cell Lymphomas by the US FDA

Channels
in Context: Structure and Function of Ion Channels in Macromolecular Complexes and Native Cells

> See All Events

Assistant
Professor – Immunology Research

Postdoctoral Studies – Stem Cells and Erythropoiesis in MDS

Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes

Postdoctoral Research Fellow – Hematopoiesis, Marrow Failure and Myeloid Leukemia

Postdoctoral Fellow – Immunology, Genetics, Precision Medicine

> See All Jobs